causal
Trial Exclusions Underestimate Real-World Harm
RCTs for regulatory approval systematically exclude the elderly, people with comorbidities, and people on multiple drugs (polypharmacy)—precisely the features that empirical evidence shows increase a drug's harms—so when the drug is later prescribed to those very populations, trials have systematically underestimated the real-world harm profile.
causalpending
Speaker
Jacob StegengaEvidence Quote
“we know that age, co-morbidity, and so-called poly-pharmacy--being on multiple drugs--itself modulates the harmfulness of the new drug. So, if you exclude those people from trials--I mean, those are the very people that end up taking new drugs”
Created: 6/13/2026, 12:09:58 AM
Your notes
Loading notes...